Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478637 | 0.87 | MAPT (0.62) | ALDH1A1MAPTKDM4ENPC1TP53 | |
| SCHEMBL2479902 | 0.82 | MAPT (0.47) | ALDH1A1MAPTKDM4ENPC1TP53 | |
| SCHEMBL15125038 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTKDM4ENPC1TP53 | |
| SCHEMBL28057380 | 0.79 | MAPT (0.50) | ALDH1A1MAPTKDM4ENPC1TP53 | |
| SCHEMBL4718485 | 0.76 | DGAT1 (0.46) | MAPTKDM4ETP53DRD3DRD1 | |
| SCHEMBL432973 | 0.76 | ALOX5 (0.55) | ALDH1A1MAPTKDM4EALOX5PTGS1 | |
| SCHEMBL27848580 | 0.74 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4ETSHRNFKB1 | |
| SCHEMBL15766789 | 0.71 | DDB1 (0.64) | ALDH1A1MAPTKDM4EALOX5PTGS1 | |
| SCHEMBL28109727 | 0.71 | ALDH1A1 (0.56) | ALDH1A1MAPTKDM4EALOX5PTGS1 | |
| SCHEMBL12058877 | 0.71 | MAPT (0.58) | ALDH1A1MAPTKDM4ENPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190309-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2013-07-25 | — | — | US | disclosed |
| US-20130190309-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2013-07-25 | — | — | US | disclosed |
| US-20130190309-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. | 2013-07-25 | — | — | US | disclosed |
| EP-2373646-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010077947-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077947-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190309-A1 | PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 2140/4885MAPT 422/4885KDM4E 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.